Law firms Pinsents and Linklaters act on latest big pharma deal as Teva sells Allergan generics business for £600m Legal Business · 6 October 2016 · 1 min read Corporate and M&A Deal watch Linklaters Pinsent Masons Pinsent Masons and Linklaters are advising on Teva Pharmaceutical Industries’ sale of UK and Ireland business Activas Generics for £603m as the Israeli firm seeks to divest assets following last year’s takeover of Allergan.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this category‘I’m not going to put a cap on growth’ – how Proskauer is capitalising on the real asset boom for its City buildLaw firmsKate Peacock19 Jun 2026DLA, Bird & Bird and Links lawyers lead the way in new Green Ambassadors cohortGreen AmbassadorsBen Wheway10 Jun 2026Bad lawyering, or the tech’s fault? Why AI slip-ups are exposing top law firmsLaw firmsTom Cox2 Jun 2026Bakers’ outgoing London chief on why the firm is doubling down on transactions in the CityLaw firmsTom Cox17 Jun 2026Top US duo tune in as Fox makes $22bn streaming acquisitionLaw firmsKate Peacock15 Jun 2026‘We’re down to earth, we’re fair, we’re ambitious’ – Browne Jacobson hits record £148.8m turnoverLaw firmsTom Cox15 Jun 2026Dealwatch: Global 100 advisers take centre stage on BlackRock-GIP $12.5bn mega dealLaw firmsAlex Ryan15 Jan 2024Dealwatch: Telegraph auction off as Barclay brothers pay off Lloyds debt with loanLaw firmsAlex Ryan8 Dec 2023Deal Watch: activity powers on as Latham and A&O lead on $19bn energy joint ventureLaw firmsMegan Mayers9 Sep 2022